This review demonstrates HMM-SA's application to uncover structural features in HIV-2 protease, indicating potential drug targets.
The rapid expansion of available three-dimensional protein structures-derived from both experimental techniques and bioinformatic predictions-offers unprecedented opportunities for drug discovery, particularly for targets that have historically been difficult to characterize. However, the effective analysis of these increasingly complex and voluminous structural datasets remains a major challenge. Efficient representations of protein conformations are essential to facilitate large-scale comparison, structural classification, and functional interpretation in therapeutic contexts. The concept of structural alphabets, introduced by Pr S. Hazout in 1999, provides a robust and scalable framework to represent local protein backbone conformations using a limited set of recurring structural motifs. This representation enables a one-dimensional encoding of three-dimensional protein structures that retains essential geometric features beyond secondary structure, while allowing systematic and interpretable analyses. In this review, we focus on HMM-SA, a structural alphabet constructed using a hidden Markov model. HMM-SA defines 27 structural motifs, including 18 regions specifically dedicated to loops, and captures the statistical dependencies between them. We present a detailed overview of the HMM-SA framework, and of the computational tools derived from this structural alphabet, developed to explore protein function, conformational variability, and the structural determinants of molecular recognition. The utility of HMM-SA is illustrated through a case study on HIV-2 protease (PR2), a critical enzyme in antiretroviral drug development. By analyzing PR2 structural asymmetry, ligand-induced conformational changes, and mutation-driven alterations, we highlight the ability of HMM-SA-based methods to identify key structural features involved in ligand specificity and resistance mechanisms, thereby advancing therapeutic target analysis.
No takes yet. Share an insight, caveat, or question.
Camproux et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: